Hepatoprotective effects of ginseng saponins in a mouse model of carbon tetrachloride-induced liver injury

Purpose: To investigate the effects of ginsenosides Rg1 and Rb1 on carbon tetrachloride (CCl4)-induced liver injury in mice.Methods: Thirty-two mice were randomly divided into four groups. In control group, mice were administered sodium carboxymethylcellulose (CMC-Na) by intraperitoneal injection for seven days. In CCl4 treatment group, mice were treated as control group for the first seven days and then intraperitoneally injected with CCl4 in olive oil on day 8. In Rb1- and Rg1-treatment group, the mice were intraperitoneally injected with Rb1 or Rg1 (each 30 mg/kg, dissolved in 0.5 % CMC-Na), respectively for seven days, followed by intraperitoneal injection with CCl4 in olive oil on day 8. Histological damage was examined by haematoxylin and eosin (H&E) staining. Serum levels of alanine aminotransferase (ALT) and aspartate transaminase (AST) were assessed enzymatically. Tissue IL-6 and IL-8 levels were measured by ELISA. Gene and protein levels of transforming growth factor (TGF)-β, Smad2, and Smad3 were analyzed by real-time PCR (RT-PCR) and western blotting, respectively.Results: CCl4 treatment caused histological damage in mouse liver, and increased the levels of ALT, AST (five-fold), IL-6 (three-fold), and IL-8 (five-fold), and elevated expressions of TGF-β, Smad2, and Smad3. Ginsenosides Rg1 or Rb1 pre-treatment attenuated liver injury by decreasing the serum levels of ALT (from 700 to 200 UI/L) AST (from 550 pg/mL to 250 pg/ml), IL-6 (from 1,100 to 750 pg/mL), and IL-8 (from 600 to 200 pg/mL), and inhibiting the expressions of TGF-β, Smad2, and Smad3.Conclusion: Ginsenosides (Rg1 and Rb1) attenuate CCl4-induced liver injury and inflammation by regulating TGF-β/Smad signalling pathway.Keywords: Ginseng saponin, Ginsenosides, Rg1, Rb1, Hepatoprotective effect, TGF-β/Smad signalling pathwa

Interleukin-10 Inhibits Bone Resorption: A Potential Therapeutic Strategy in Periodontitis and Other Bone Loss Diseases

Periodontitis and other bone loss diseases, decreasing bone volume and strength, have a significant impact on millions of people with the risk of tooth loss and bone fracture. The integrity and strength of bone are maintained through the balance between bone resorption and bone formation by osteoclasts and osteoblasts, respectively, so the loss of bone results from the disruption of such balance due to increased resorption or/and decreased formation of bone. The goal of therapies for diseases of bone loss is to reduce bone loss, improve bone formation, and then keep healthy bone density. Current therapies have mostly relied on longterm medication, exercise, anti-inflammatory therapies, and changing of the life style. However there are some limitations for some patients in the effective treatments for bone loss diseases because of the complexity of bone loss. Interleukin-10 (IL-10) is a potent anti-inflammatory cytokine, and recent studies have indicated that IL-10 can contribute to the maintenance of bone mass through inhibition of osteoclastic bone resorption and regulation of osteoblastic bone formation. This paper will provide a brief overview of the role of IL-10 in bone loss diseases and discuss the possibility of IL-10 adoption in therapy of bone loss diseases therapy

Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.

BACKGROUND: Coronavirus disease 2019 (COVID-19), caused by a novel corinavirus (later named SARS-CoV-2 virus), was fistly reported in Wuhan, Hubei Province, China towards the end of 2019. Large-scale spread within China and internationally led the World Health Organization to declare a Public Health Emergency of International Concern on 30th January 2020. The clinical manifestations of COVID-19 virus infection include asymptomatic infection, mild upper respiratory symptoms, severe viral pneumonia with respiratory failure, and even death. There are no antivirals of proven clinical efficacy in coronavirus infections. Remdesivir (GS-5734), a nucleoside analogue, has inhibitory effects on animal and human highly pathogenic coronaviruses, including MERS-CoV and SARS-CoV, in in vitro and in vivo experiments. It is also inhibitory against the COVID-19 virus in vitro. The aim of this study is to assess the efficacy and safety of remdesivir in adult patients with severe COVID-19. METHODS: The protocol is prepared in accordance with the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines. This is a phase 3, randomized, double-blind, placebo-controlled, multicentre trial. Adults (≥ 18 years) with laboratory-confirmed COVID-19 virus infection, severe pneumonia signs or symptoms, and radiologically confirmed severe pneumonia are randomly assigned in a 2:1 ratio to intravenously administered remdesivir or placebo for 10 days. The primary endpoint is time to clinical improvement (censored at day 28), defined as the time (in days) from randomization of study treatment (remdesivir or placebo) until a decline of two categories on a six-category ordinal scale of clinical status (1 = discharged; 6 = death) or live discharge from hospital. One interim analysis for efficacy and futility will be conducted once half of the total number of events required has been observed. DISCUSSION: This is the first randomized, placebo-controlled trial in COVID-19. Enrolment began in sites in Wuhan, Hubei Province, China on 6th February 2020. TRIAL REGISTRATION: ClinicalTrials.gov: NCT04257656. Registered on 6 February 2020

A fast algorithm for constructing orthogonal multiwavelets

Multiwavelets possess some nice features that uniwavelets do not. A consequence of this is that multiwavelets provide interesting applications in signal processing as well as in other fields. As is well known, there are perfect construction formulas for the orthogonal uniwavelet. However, a good formula with a similar structure for multiwavelets does not exist. In particular, there are no effective methods for the construction of multiwavelets with a dilation factor (, ). In this paper, a procedure for constructing compactly supported orthonormal multiscaling functions is first given. Based on the constructed multiscaling functions, we then propose a method of constructing multiwavelets, which is similar to that for constructing uniwavelets. In addition, a fast numerical algorithm for computing multiwavelets is given. Compared with traditional approaches, the algorithm is not only faster, but also computationally more efficient. In particular, the function values of several points are obtained simultaneously by using our algorithm once. Finally, we give three examples illustrating how to use our method to construct multiwavelets

Image Encryption Technique Combining Compressive Sensing with Double Random-Phase Encoding

A new image compression-encryption method based on compressive sensing and double random-phase encoding is proposed, which can complete image compression and encryption simultaneously. We utilize the hyperchaotic system to generate a measurement matrix and two random-phase masks first. Then the original image is measured by measurement matrix to accomplish encryption and compression at the same time, next the compressed image is reencrypted by the double random-phase encoding technique with the two random-phase masks, and lastly the resulting image is confused and diffused by using hyperchaotic system simultaneously. Some numerical simulations verify the validity and the reliability of the proposed algorithm

A novel method of constructing compactly supported orthogonal scaling functions from splines

Abstract A novel construction of compactly supported orthogonal scaling functions and wavelets with spline functions is presented in this paper. Let M n $M_{n}$ be the center B-spline of order n, except for the case of order one, we know M n $M_{n}$ is not orthogonal. But by the formula of orthonormalization procedure, we can construct an orthogonal scaling function corresponding to M n $M_{n}$ . However, unlike M n $M_{n}$ itself, this scaling function no longer has compact support. To induce the orthogonality while keeping the compact support of M n $M_{n}$ , we put forward a simple, yet efficient construction method that uses the formula of orthonormalization procedure and the weighted average method to construct the two-scale symbol of some compactly supported orthogonal scaling functions